Where can I find news about CHMMF?

The latest headlines, third-party analysis, and SEC filings for Chimeric Therapeutics Limited (CHMMF) are listed on this page. Headlines come from across the financial press; filings come directly from SEC EDGAR.

Where are CHMMF's SEC filings?

Chimeric Therapeutics Limited (CHMMF)'s 10-K (annual report), 10-Q (quarterly report), 8-K (current report), and proxy filings are listed in the SEC Filings section on this page with direct links to the official EDGAR copies.

Where are CHMMF's earnings call transcripts?

Full earnings call transcripts for Chimeric Therapeutics Limited (CHMMF) — prepared remarks plus speaker-by-speaker analyst Q&A — live on the Earnings tab, alongside the Earnings Reports section that links each quarter's press release and SEC report.

CHMMF

Chimeric Therapeutics Limited

OTC·Biotechnology · Healthcare

$0.10$0.00+0.00%

Market cap$4.10M·Market closed·Aug 26 8:00 PM UTC

News & Analysis

Chimeric Therapeutics secures FDA Orphan Drug Designation for CHM CDH17 in gastric cancer
Chimeric Therapeutics Ltd (ASX:CHM, OTC:CHMMF) has received Orphan Drug Designation from the US Food and Drug Administration (FDA) for its CHM CDH17 cell...
proactiveinvestors.comDec 8, 2025 · 8:12 AM
Imugene secures FDA backing for Azer-cel registration pathway
Imugene Ltd (ASX:IMU, OTC:IUGNF) has won crucial backing from the US Food and Drug Administration (FDA), with written minutes from a recent Type C meeting...
proactiveinvestors.comDec 8, 2025 · 7:32 AM
Kairos Minerals secures mining agreement with Nyamal Aboriginal Corporation for Mt York Gold Project
Kairos Minerals Ltd (ASX:KAI, OTCQB:KAIFF) has signed a Mining Agreement with Nyamal Aboriginal Corporation (NAC) covering the Mt York Gold Project in the...
proactiveinvestors.comDec 8, 2025 · 6:53 AM
Chimeric Therapeutics receives $4.5 million R&D tax incentive refund
Chimeric Therapeutics Ltd (ASX:CHM, OTC:CHMMF) has received a research and development (R&D) tax incentive refund of $4,497,886 under the Australian...
proactiveinvestors.comNov 24, 2025 · 7:48 AM
Altech draws interest from top-tier battery manufacturer as Silumina Anodes™ hit 1,000-cycle mark
Altech Batteries Ltd (ASX:ATC, OTC:ALTHF) has attracted fresh industry attention after one of the world’s largest electric vehicle battery manufacturers...
proactiveinvestors.comNov 24, 2025 · 5:47 AM
Vaultz completes Xapo Bank onboarding
Vaultz Capital PLC (AQSE:V3TC, OTCQB:VZTCF) told investors it has completed onboarding with Xapo Bank, marking the start of a new custody arrangement for...
proactiveinvestors.comNov 24, 2025 · 2:51 AM

SEC Filings

No recent filings indexed.

Frequently Asked Questions About CHMMF

Where can I find news about CHMMF?: The latest headlines, third-party analysis, and SEC filings for Chimeric Therapeutics Limited (CHMMF) are listed on this page. Headlines come from across the financial press; filings come directly from SEC EDGAR.
Where are CHMMF's SEC filings?: Chimeric Therapeutics Limited (CHMMF)'s 10-K (annual report), 10-Q (quarterly report), 8-K (current report), and proxy filings are listed in the SEC Filings section on this page with direct links to the official EDGAR copies.
Where are CHMMF's earnings call transcripts?: Full earnings call transcripts for Chimeric Therapeutics Limited (CHMMF) — prepared remarks plus speaker-by-speaker analyst Q&A — live on the Earnings tab, alongside the Earnings Reports section that links each quarter's press release and SEC report.

Chimeric Therapeutics Limited

Frequently Asked Questions About CHMMF

Chimeric Therapeutics Limited

Chimeric Therapeutics secures FDA Orphan Drug Designation for CHM CDH17 in gastric cancer

Imugene secures FDA backing for Azer-cel registration pathway

Kairos Minerals secures mining agreement with Nyamal Aboriginal Corporation for Mt York Gold Project

Chimeric Therapeutics receives $4.5 million R&D tax incentive refund

Altech draws interest from top-tier battery manufacturer as Silumina Anodes™ hit 1,000-cycle mark

Vaultz completes Xapo Bank onboarding

Frequently Asked Questions About CHMMF

Chimeric Therapeutics secures FDA Orphan Drug Designation for CHM CDH17 in gastric cancer

Imugene secures FDA backing for Azer-cel registration pathway

Kairos Minerals secures mining agreement with Nyamal Aboriginal Corporation for Mt York Gold Project

Chimeric Therapeutics receives $4.5 million R&D tax incentive refund

Altech draws interest from top-tier battery manufacturer as Silumina Anodes™ hit 1,000-cycle mark

Vaultz completes Xapo Bank onboarding